These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 36169097)
21. Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease: A Postmarketing Surveillance in Japan (SAKURA Study). Miura M; Kobayashi T; Igarashi T; Hamada H; Iwata N; Sasaki Y; Matsukawa M; Sato N; Kubo H; Takei S Pediatr Infect Dis J; 2020 Jan; 39(1):41-47. PubMed ID: 31815838 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241 [TBL] [Abstract][Full Text] [Related]
26. Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis. Xue LJ; Wu R; Du GL; Xu Y; Yuan KY; Feng ZC; Pan YL; Hu GY Clin Rev Allergy Immunol; 2017 Jun; 52(3):389-400. PubMed ID: 27550227 [TBL] [Abstract][Full Text] [Related]
27. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Gordon M; Taylor K; Akobeng AK; Thomas AG Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347 [TBL] [Abstract][Full Text] [Related]
29. Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. Vande Casteele N; Oyamada J; Shimizu C; Best BM; Capparelli EV; Tremoulet AH; Burns JC Clin Pharmacokinet; 2018 Dec; 57(12):1593-1601. PubMed ID: 29623653 [TBL] [Abstract][Full Text] [Related]
30. The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease. Ebato T; Ogata S; Ogihara Y; Fujimoto M; Kitagawa A; Takanashi M; Ishii M J Pediatr; 2017 Dec; 191():140-144. PubMed ID: 29173297 [TBL] [Abstract][Full Text] [Related]
31. Kawasaki disease: a comprehensive review of treatment options. Patel RM; Shulman ST J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265 [TBL] [Abstract][Full Text] [Related]
32. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials]. Hu JW; Zhou ZS; Yang L; Zheng CN; Wang KD Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1259-64. PubMed ID: 21756798 [TBL] [Abstract][Full Text] [Related]
33. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Chande N; Patton PH; Tsoulis DJ; Thomas BS; MacDonald JK Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD000067. PubMed ID: 26517527 [TBL] [Abstract][Full Text] [Related]
35. Antibiotics for induction and maintenance of remission in Crohn's disease. Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030 [TBL] [Abstract][Full Text] [Related]
36. Interventions for necrotizing soft tissue infections in adults. Hua C; Bosc R; Sbidian E; De Prost N; Hughes C; Jabre P; Chosidow O; Le Cleach L Cochrane Database Syst Rev; 2018 May; 5(5):CD011680. PubMed ID: 29851032 [TBL] [Abstract][Full Text] [Related]
37. The impact of biological interventions for ulcerative colitis on health-related quality of life. LeBlanc K; Mosli MH; Parker CE; MacDonald JK Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522 [TBL] [Abstract][Full Text] [Related]
38. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908 [TBL] [Abstract][Full Text] [Related]
39. Intravenous immunoglobulin for the treatment of childhood encephalitis. Iro MA; Martin NG; Absoud M; Pollard AJ Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011367. PubMed ID: 28967695 [TBL] [Abstract][Full Text] [Related]
40. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]